Straits Times Index
3,410.81 -29.07 (-0.85%) S&P 500
5,567.19 +30.17 (+0.54%) Dow
39,375.87 +67.87 (+0.17%) Nasdaq
18,352.76 +164.46 (+0.90%) Bitcoin USD
56,311.04 -1,609.60 (-2.78%) CMC Crypto 200
1,186.69 -22.00 (-1.82%)
BIIB Jul 2024 220.000 call
| Previous close | 9.34 |
| Open | 4.30 |
| Bid | 1.65 |
| Ask | 9.60 |
| Strike | 220.00 |
| Expiry date | 2024-07-05 |
| Day's range | 4.30 - 6.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Insider MonkeyBiogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
ClearBridge Investments, an investment management company, released its “ClearBridge Value Equity Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The strategy outperformed the Russell 1000 Value Index in the first quarter. On an absolute basis, the strategy has gained 9 out of eleven sectors it invested in during […]
GlobeNewswireBiogen Completes Acquisition of Human Immunology Biosciences
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). “We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indicat
ReutersEisai and Biogen launch Alzheimer's drug Leqembi in China
Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer. China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.
